Anakinra treatment in patients with acute Kawasaki disease with coronary artery aneurysms: A Phase I/IIa trial
To determine the safety, pharmacokinetics, and immunomodulatory effects of two- to six-weeks of anakinra in patients with acute KD Kawasaki disease with coronary artery aneurysms (CAA).
source https://www.jpeds.com/article/S0022-3476(21)01242-7/fulltext?rss=yes
source https://www.jpeds.com/article/S0022-3476(21)01242-7/fulltext?rss=yes
Comments
Post a Comment